Results 1 to 10 of about 69,008 (285)

Preclinical characterization of 3p-C-DEPA-NCS and 3p-C-DEPA-TFP-PEG4 as potential Actinium-225 bifunctional chelators using DOTA-NCS and macropa-NCS as benchmarks [PDF]

EJNMMI Radiopharmacy and Chemistry
Background Actinium-225 (225Ac) based targeted alpha therapies (TAT) have emerged as a promising strategy for the treatment of several cancer types due to its favourable decay properties, including high linear energy transfer and short particle range ...
Jessica Pougoue Ketchemen, Stephen Ahenkorah, Emmanuel Nwangele, Siphelele Siphesihle Pearl Malaza, Maarten Ooms, Thomas Cardinaels, Simon Leekens, Frederik Cleeren, Humphrey Fonge   +8 more
doaj   +2 more sources

Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study

Breast, 2022
Purpose: To gauge the effects of treatment practices on prognosis for older patients with HER2-positive early breast cancer, particularly to determine whether adjuvant trastuzumab alone can offer benefit over no adjuvant therapy.
Masataka Sawaki, Naruto Taira, Yukari Uemura, Tsuyoshi Saito, Shinichi Baba, Kokoro Kobayashi, Hiroaki Kawashima, Michiko Tsuneizumi, Noriko Sagawa, Hiroko Bando, Masato Takahashi, Miki Yamaguchi, Tsutomu Takashima, Takahiro Nakayama, Masahiro Kashiwaba, Toshiro Mizuno, Yutaka Yamamoto, Hiroji Iwata, Tatsuya Toyama, Koichiro Tsugawa, Takuya Kawahara, Hirofumi Mukai   +21 more
doaj   +1 more source

Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

Breast, 2021
Background: Trastuzumab-dkst is a biosimilar of trastuzumab. The phase 3 HERITAGE trial demonstrated equivalent overall response rate (ORR) with trastuzumab-dkst or originator trastuzumab at 24 weeks in patients with HER2-positive metastatic breast ...
Hope S. Rugo, Eduardo J. Pennella, Unmesh Gopalakrishnan, Miguel Hernandez-Bronchud, Jay Herson, Hans Friedrich Koch, Subramanian Loganathan, Sarika Deodhar, Ashwani Marwah, Alexey Manikhas, Igor Bondarenko, Joseph D. Parra, Maria Luisa T. Abesamis-Tiambeng, Charuwan Akewanlop, Ihor Vynnychenko, Virote Sriuranpong, Sirshendu Roy, Eduardo Patricio Yanez Ruiz, Abhijit Barve, Cornelius F. Waller   +19 more
doaj   +1 more source

Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer

Technology in Cancer Research & Treatment, 2023
Introduction: This study aimed to compare the efficacy and safety of docetaxel + trastuzumab + pertuzumab and docetaxel + carboplatin + trastuzumab + pertuzumab for treating HER2-positive breast cancer.
Binwei Lin MM, Jinjia Fan MM, Fang Liu MD, Yixue Wen MM, Jie Li MD, Feng Gao MD, Yu Zhang MD, Gang Feng MM, Xiaobo Du MD, Wenzhi Chen MD   +9 more
doaj   +1 more source

Incidence of central nervous system metastases in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with trastuzumab: A meta-analysis

Clinics, 2021
This study aimed to estimate the incidence of central nervous system (CNS) metastases in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) treated with trastuzumab.
Xue Bai, Xue Lin, Jin Song, Jia-han Chang, Li-li Han, Cibo Fan   +5 more
doaj   +1 more source

Trastuzumab [PDF]

The Oncologist, 2011
Abstract Trastuzumab is standard of care in the treatment of human epidermal growth factor receptor (HER)-2+ early and advanced breast cancer. Recently, it has been approved for the treatment of HER-2+ advanced gastric cancer. Trastuzumab is an IgG1 humanized monoclonal antibody administered by intravenous infusion on a weekly or three ...
Boekhout, A.H., Beijnen, J.H., Schellens, J.H.M.   +2 more
openaire   +3 more sources

Synthesized Anti-HER2 Trastuzumab-MCC-DM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity [PDF]

Iranian Journal of Immunology, 2023
Background: Trastuzumab is a humanized monoclonal antibody that targets site-specifically human epidermal growth factor-2 receptor (HER2) cell surface antigen overexpressed in approximately 20% of human breast carcinomas. Despite its positive therapeutic
Soodabeh Shafiee, Roya Mirzaei, Malihe Salehi, Neda Jalili, Amir Taheri, Leila Farahmand   +5 more
doaj   +1 more source

Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression

Journal for ImmunoTherapy of Cancer, 2023
Background The success of HER2-positive (HER2+) breast cancer treatment with trastuzumab, an antibody that targets HER2, relies on immune response. We demonstrated that TNFα induces mucin 4 (MUC4) expression, which shields the trastuzumab epitope on the ...
Sofia Bruni, Florencia L Mauro, Cecilia J Proietti, Rosalia I Cordo-Russo, Martin A Rivas, Gloria Inurrigarro, Agustina Dupont, Dario Rocha, Elmer A Fernández, Ernesto Gil Deza, Daniel Lopez Della Vecchia, Sabrina Barchuk, Silvina Figurelli, David Lasso, Adrián D Friedrich, María C Santilli, María V Regge, Gabriel Lebersztein, Claudio Levit, Fabiana Anfuso, Teresa Castiglione, Patricia V Elizalde, Maria F Mercogliano, Roxana Schillaci   +23 more
doaj   +1 more source

Exosomal Linc00969 induces trastuzumab resistance in breast cancer by increasing HER-2 protein expression and mRNA stability by binding to HUR

Breast Cancer Research, 2023
Background Breast cancer (BC) is the most common malignant disease in female patients worldwide. In HER-2+ BC patients, trastuzumab therapy is associated with a better prognosis.
Cuiwei Liu, Chong Lu, Lamu Yixi, Jiaxing Hong, Fang Dong, Shengnan Ruan, Ting Hu, Xiangwang Zhao   +7 more
doaj   +1 more source

Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity

Breast Cancer Research, 2020
Background ErbB2/HER2 oncoprotein often drives breast cancers (BCs) which are treated with the anti-ErbB2 antibody trastuzumab. The efficacy of trastuzumab-based metastatic BC therapies is routinely assessed by imaging studies.
Arik Durcker, Byong Hoon Yoo, Iman Aftab Khan, Dongsic Choi, Laura Montermini, Xiaoyang Liu, Sanja Jovanovic, Tallal Younis, Kirill V. Rosen   +8 more
doaj   +1 more source